Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pfizer's Xeljanz elected in US as 1st JAK in RA

This article was originally published in Scrip

Executive Summary

The US FDA on 6 November sanctioned pharma giant Pfizer's Xeljanz (tofacitinib citrate) as a treatment for adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response or are intolerant to methotrexate – granting the approval two weeks ahead of the medicine's action goal date.

You may also be interested in...



AbbVie’s Rinvoq Delay By US FDA Could Foreshadow More Trouble For JAKs

The expansion of upadacitinib for a new indication in psoriatic arthritis has been pushed out three months to late in the second quarter.

First Phase III Results Keep Pfizer's Abrocitinib Among JAK Leaders In Atopic Dermatitis

Pfizer follows Lilly as the second company to report positive top-line Phase III results in AD for a JAK inhibitor. Safety is a key concern for the class, but Pfizer did not provide any details about abrocitinib's side effects.

Moderna's Valera Takes mRNA Approach To Combat Zika

With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.

Topics

Related Companies

UsernamePublicRestriction

Register

SC019358

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel